Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
Am J Clin Pathol ; 154(2): 266-276, 2020 07 07.
Artigo em Inglês | MEDLINE | ID: mdl-32525522

RESUMO

OBJECTIVES: Management of colorectal cancer warrants mutational analysis of KRAS/NRAS when considering anti-epidermal growth factor receptor therapy and BRAF testing for prognostic stratification. In this multicenter study, we compared a fully integrated, cartridge-based system to standard-of-care assays used by participating laboratories. METHODS: Twenty laboratories enrolled 874 colorectal cancer cases between November 2017 and December 2018. Testing was performed on the Idylla automated system (Biocartis) using the KRAS and NRAS-BRAF cartridges (research use only) and results compared with in-house standard-of-care testing methods. RESULTS: There were sufficient data on 780 cases to measure turnaround time compared with standard assays. In-house polymerase chain reaction (PCR) had an average testing turnaround time of 5.6 days, send-out PCR of 22.5 days, in-house Sanger sequencing of 14.7 days, send-out Sanger of 17.8 days, in-house next-generation sequencing (NGS) of 12.5 days, and send-out NGS of 20.0 days. Standard testing had an average turnaround time of 11 days. Idylla average time to results was 4.9 days with a range of 0.4 to 13.5 days. CONCLUSIONS: The described cartridge-based system offers rapid and reliable testing of clinically actionable mutation in colorectal cancer specimens directly from formalin-fixed, paraffin-embedded tissue sections. Its simplicity and ease of use compared with other molecular techniques make it suitable for routine clinical laboratory testing.


Assuntos
Neoplasias Colorretais/genética , GTP Fosfo-Hidrolases/genética , Proteínas de Membrana/genética , Proteínas Proto-Oncogênicas p21(ras)/genética , Adulto , Idoso , Idoso de 80 Anos ou mais , Biomarcadores Tumorais/genética , Análise Mutacional de DNA , Feminino , Sequenciamento de Nucleotídeos em Larga Escala , Humanos , Masculino , Pessoa de Meia-Idade , Padrão de Cuidado , Fatores de Tempo
3.
Insight ; 29(4): 17, 19-21, 2004.
Artigo em Inglês | MEDLINE | ID: mdl-15693468

RESUMO

Creutzfeldt-Jakob disease belongs to a group of rapidly progressive, fatal neurological disorders. Several cases of iatrogenic Creutzfeldt-Jakob disease (CJD) have been reported in the literature after neurosurgery and corneal grafting. The total number of people affected by CJD is unknown at this time, and it will remain unknown for some time to come. High infectious risks classification includes the brain, spinal cord, and eyes. Transmissible spongiform encephalopathy (TSE) prions are resistant to steam sterilization, dry heat, ethylene oxide gas, and chemical disinfection. Prevention of prion transmission must be taken into account in daily practice. Efficient sterilization procedures should be determined.


Assuntos
Síndrome de Creutzfeldt-Jakob , Encefalopatia Espongiforme Bovina , Controle de Infecções/métodos , Centros Médicos Acadêmicos , Animais , Bovinos , Causalidade , Síndrome de Creutzfeldt-Jakob/diagnóstico , Síndrome de Creutzfeldt-Jakob/epidemiologia , Síndrome de Creutzfeldt-Jakob/terapia , Síndrome de Creutzfeldt-Jakob/transmissão , Infecção Hospitalar/etiologia , Infecção Hospitalar/prevenção & controle , Surtos de Doenças/prevenção & controle , Surtos de Doenças/estatística & dados numéricos , Desinfecção/métodos , Encefalopatia Espongiforme Bovina/diagnóstico , Encefalopatia Espongiforme Bovina/epidemiologia , Encefalopatia Espongiforme Bovina/terapia , Encefalopatia Espongiforme Bovina/transmissão , Contaminação de Equipamentos/prevenção & controle , Humanos , Transmissão de Doença Infecciosa do Paciente para o Profissional/prevenção & controle , Papel do Profissional de Enfermagem , Pennsylvania/epidemiologia , Estados Unidos/epidemiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA